Compare Expedia Group Inc (EXPE) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Eli Lilly And Co — how do they compare? Expedia Group Inc trades at $268.33 (market cap $32.06B), while Eli Lilly And Co trades at $1,173.57 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 32.1× Expedia Group Inc's market cap, and Expedia Group Inc pays the higher dividend (0.66%). Which is the better fit depends on your goals.
| EXPE | LLY | |
|---|---|---|
Market Cap | $32.06B | $1.03T |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $1.24K |
52-Week Low | $178.06 | $625.65 |
Enterprise Value | $30.97B | $1.07T |
Dividend Yield | 0.66% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $264.76, down 0.57% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with revenue growth to $14.73B in 2025 and consistent earnings beats, including Q1 2026 EPS of $1.96 versus $1.41 expected. Recent developments include a strategic partnership with Allegiant Travel and positive analyst coverage highlighting growth potential. Valuation metrics include a P/E of 23.6 and P/S of 2.29, indicating reasonable pricing relative to peers.
The outlook for EXPE is positive, driven by robust travel demand, strategic initiatives, and a consensus price target of $292.09 implying ~10% upside. Key risks include macroeconomic sensitivity affecting travel spending and competitive pressures. Institutional sentiment is bullish with 45% buy ratings, though investors should monitor execution on growth targets and industry cyclicality.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
